Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Stem-Cell Therapy for ED & the Predatory Clinic Industry

Preclinical Promise vs Unregulated Stem-Cell Clinics, FDA Warning Letters, and 'Stem-Cell Tourism'

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
No FDA-approved stem-cell product for ED; many clinics are subject of FDA warnings

Reference only. Not medical advice.

What can go wrong

Documented harms from unregulated stem-cell clinics include infection, embolism, tumor/ectopic-tissue formation, and (in non-ED contexts) blindness from intraocular injection, the FDA has cited such events. For ED specifically, the dominant harms are financial exploitation, false hope, and forgoing effective first-line care. 'Stem-cell tourism' abroad removes regulatory protection and complicates follow-up for adverse events. Products are frequently misbranded and may be non-sterile.

This is something to take to a clinician. The Atlas can tell you what is known about stem-cell therapy for ed & the predatory clinic industry in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Stem-cell therapy for ED has genuine preclinical support, in diabetic and cavernous-nerve-injury rat models, mesenchymal/adipose-derived stem cells improve erectile parameters, and paracrine signaling (not engraftment) appears to drive the effect. Human data are minimal: a few small uncontrolled pilots and one notable Danish pilot (Haahr et al.) in post-prostatectomy men. There is NO FDA-approved stem-cell product for ED. Meanwhile a predatory cash-pay industry sells unproven 'stem cell' injections, often actually amniotic, umbilical-cord, or 'exosome' products with few or no live cells, for $5,000-$25,000+. The FDA has issued numerous warning letters and won a 2019 injunction (US v. US Stem Cell Clinic) over unapproved adipose stem-cell products; 'stem-cell tourism' to clinics abroad adds documented safety harms.

Real preclinical science, a tiny pilot RCT, and a predatory cash-pay clinic industry the FDA has repeatedly sanctioned.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Post-prostatectomy ED (investigational pilots)
  • Diabetic/vasculogenic ED (preclinical)
  • Marketed broadly by clinics with no validation

How it is supposed to work

Mesenchymal stem cells (from bone marrow or adipose tissue) were originally thought to engraft and differentiate into new endothelium/smooth muscle. The current understanding is largely paracrine: transplanted cells transiently secrete growth factors, cytokines, and extracellular vesicles (exosomes) that reduce apoptosis, promote angiogenesis, and protect cavernous nerves. In rodent models of diabetic ED and cavernous-nerve injury this improves intracavernosal pressure responses. Translating a transient paracrine effect in rats into durable human benefit is unproven, and most commercial 'stem cell' products contain few viable cells anyway.

The catch: most 'stem cell' products sold for ED have no live stem cells

Amniotic and umbilical-cord 'stem cell' products marketed to clinics are typically processed/frozen tissue with negligible viable cells by the time of injection, independent testing (e.g., Berger et al. 2019, analyzing commercial amniotic/cord products) found few or no living stem cells. So patients pay stem-cell prices for an acellular product. The legitimate science (Haahr pilots, animal models) uses freshly isolated autologous cells under research protocols, categorically different from the off-the-shelf vials clinics inject. This bait-and-switch is the core of the fraud landscape.

What people get wrong

  • Often saidStem cells regrow your erectile tissue

    ActuallyHuman evidence is limited to tiny uncontrolled pilots. No durable regeneration of erectile tissue has been demonstrated in controlled trials.

  • Often saidThe injection contains live stem cells

    ActuallyMany off-the-shelf amniotic/cord products contain few or no viable cells; patients often pay for an acellular product.

  • Often saidIt's FDA-approved / FDA-registered, so it's safe

    ActuallyFDA tissue registration is not approval. The FDA has issued warning letters and obtained injunctions against unapproved stem-cell products.

Who profits, and who pushes back

  • U.S. Food and Drug Administration

    Pushes backOffice of Tissues and Advanced Therapies

    Unapproved stem-cell products marketed for serious conditions can be both ineffective and dangerous; consumers should be wary of clinics offering them outside FDA-authorized trials.

  • Paul Knoepfler, PhD

    Pushes backStem-cell biologist (UC Davis), tracks predatory clinics

    The unproven stem-cell clinic industry sells hope at high prices with little or no rigorous evidence, and ED is a common target market.

What we do not know

  • Can controlled trials confirm the Haahr post-prostatectomy signal?
  • Is the benefit paracrine/transient or durable?
  • Can autologous freshly-isolated protocols be standardized and regulated?
  • How many marketed 'stem cell' ED products contain any live cells at all?

At a glance

Strongest data
Animal models + tiny human pilots
Human pilot
Haahr et al. (post-prostatectomy), uncontrolled
FDA-approved ED stem-cell product
None
Typical clinic price
$5,000-$25,000+ cash

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Stem-Cell Therapy for ED & the Predatory Clinic Industry. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Haahr et al. (EBioMedicine)2016/2018

    Pilot of autologous adipose-derived regenerative cells in post-prostatectomy ED; some men regained erectile function, but uncontrolled and small

  • Berger et al. (assessment of commercial products)2019

    Independent analysis found commercially marketed amniotic/cord 'stem cell' products contained few or no viable stem cells

  • Lin/Lue group preclinical work2010s

    Adipose-derived stem cells improved erectile function in diabetic and nerve-injury rat models, largely via paracrine signaling